ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

165
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
10 Feb 2024 06:47Broker

HSIE Results Daily: Lupin, Cummins, Apollo Tyres, Kalpataru Projects International

Lupin: EBITDA growth (+98% YoY and +11% QoQ) was led by 20% YoY sales growth (US: flat QoQ, India +13% YoY, EMEA: +36% YoY and +71% RoW),

Logo
442 Views
Share
09 Feb 2024 06:05Broker

Axis Research Scorecard Report for Jan 2024

Post Budget Analysis and Stock Ideas: It gives us immense joy to announce our Post Budget Analysis and Stock Ideas for 2024-25.

Logo
308 Views
Share
bearishInfosys Ltd
06 Feb 2024 06:50

India: Free Float Changes & Passive Flows in February

Changes to shareholding patterns could lead to changes in float for some stocks in local/global indices. Passive trackers will need to trade over 3...

Logo
456 Views
Share
bullishCipla Ltd
30 Jan 2024 23:36

Cipla (CIPLA IN): Q3FY24 Result- Continued Growth Trajectory Across Key Markets; Positive Outlook

​Cipla reports strong Q3FY24 result with 14% YoY sales growth and 24.2% EBITDA margin. US business achieves record high sales. Full-year EBITDA...

Logo
295 Views
Share
24 Jan 2024 07:34Broker

Pharmaceuticals: US Generic Growth to Stay, Selective on Structural Play

The pharmaceutical sector, emerging from the volatility of the past two post-pandemic and geopolitically tumultuous years, is now on a recovery...

Logo
224 Views
Share
x